Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTX·NASDAQ

$36.21

-1.7%
HealthcareBiotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$3.90B
EPS-1.6300
P/E Ratio-22.21
Earnings Date08/06/2026

No Dividend Yield Data

EWTX has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

EWTX has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

EWTX has not reported any net dividends paid values in the available annual periods.

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. Dividend History

EWTX · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

EWTX Dividend Payment History

EWTX · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
ewtx

Edgewise Therapeutics, Inc. Payout Ratio Analysis

EWTX · NASDAQ
Dividends Paid
0.00
2025
Net Income
-167.79M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.